The data says one thing, price says another...

Oversold or overlooked 🤔

April 06, 2026

*This email contains promotional content

Happy Monday, Folks - Jeff Bishop here!

The markets enjoyed a strong rebound last week, with the S&P 500 and the Nasdaq each climbing about 3%.

Stock futures were down last night as traders juggled rising oil prices and fresh escalation risks in the Iran conflict.

Crude is pushing higher again, and markets are about to digest Friday’s jobs report for the first time, which came in stronger than expected on the surface — but with some cracks underneath.

In other words: volatility isn’t going anywhere.

And that’s exactly the kind of environment where small-cap opportunities can start making outsized moves.

One stock I’ve been tracking just jumped 6.4% on Friday, but that move might only be the beginning.

This is a sub-$1 stock with HUGE potential right now. 

There’s a major story developing as we speak. We’re talking about a biotech with:

👉 Positive Phase 2 clinical data already in hand

👉 Independent validation from a top investigator confirming ~80% response rates

👉 A potential ~$8 BILLION combined market opportunity

The company is developing a first-of-its-kind treatment targeting the most common cancer in the world, with a delivery method that could potentially replace surgery for millions of patients.

Plus, a second program targeting a massive prostate cancer market — with a differentiated approach that could solve real limitations in current therapies.

And all of this is happening while analysts are still maintaining bullish ratings, the company is heading into key FDA discussions, and partnership conversations could be on the table this year.

I put together a full breakdown of the opportunity — including the data, the setup, and what I’m watching next.

Make sure you take a look before the bell this morning. It already started to move on Friday, and in this kind of market, momentum can build fast.

To Your Success,

(ALL are welcome)

DISCLAIMER: This publication is owned and operated by Sherwood Ventures LLC (“SV”). Full disclaimer: https://bullseyealerts.com/disclaimer/.

NOT INVESTMENT ADVICE: We are a financial publisher, not a registered investment advisor. Content provided is for informational, educational, and promotional purposes only and should not be considered investment advice or a recommendation to buy or sell any security.

*PAID PROMOTION/COMPENSATION DISCLOSURE: SV has received thirty five thousand dollars (cash) for a one day marketing program on April 6, 2026 for marketing efforts to increase public awareness of the company mentioned on this page HERE. Please scroll to the bottom for full disclosure details including historical records (if applicable). As SV has received compensation from companies, these parties have financial interests in the securities referenced. SV and its affiliates may buy, sell, or hold positions in securities mentioned at any time without notice.

RISK WARNING: Investing involves substantial risk. Securities discussed may be highly speculative and volatile. Past performance is not indicative of future results, and you may lose some or all of your investment. Always consult a licensed financial professional before making investment decisions.